.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE30_NirmatrelvirAndRitonavir.NirmatrelvirAndRitonavir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE30_NirmatrelvirAndRitonavir.NirmatrelvirAndRitonavir| name: | NirmatrelvirAndRitonavir |
| ATC code: | J05AE30 | route: | oral |
| n-compartments | 1 |
Nirmatrelvir and ritonavir is a combination antiviral therapy used primarily in the treatment of COVID-19. Nirmatrelvir is a SARS-CoV-2 3CL protease inhibitor, while ritonavir acts as a pharmacokinetic enhancer by inhibiting CYP3A-mediated metabolism, thereby increasing plasma concentrations of nirmatrelvir. This combination (marketed as Paxlovid) is approved for emergency use and treatment of COVID-19 in many countries.
Representative pharmacokinetic parameters for nirmatrelvir/ritonavir in healthy adult subjects after oral administration.
Hammond, J, et al., & Rusnak, JM (2022). Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. The New England journal of medicine 386(15) 1397–1408. DOI:10.1056/NEJMoa2118542 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35172054
Gerhart, J, et al., & Damle, B (2024). A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir. Clinical pharmacokinetics 63(1) 27–42. DOI:10.1007/s40262-023-01339-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/38177893
Pagliano, P, et al., & Ascione, T (2023). Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants. Expert opinion on drug discovery 18(12) 1301–1311. DOI:10.1080/17460441.2023.2248879 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37614103